Navigation Links
Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare To Care."
Date:7/13/2012

WASHINGTON, July 13, 2012 /PRNewswire-iReach/ -- Science Translational Medicine, the newest journal from the American Association for the Advancement of Science (AAAS), and the Days of Molecular Medicine Global Foundation (DMM GF) announced today the launch of Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare to Care," a three-day meeting which will be held in Vienna, Austria from October 8 through October 10, 2012.

Taking place at the Palais de Lichtenstein, and featuring an international roster of academic, industrial and government scientists, headlined by Nobel Laureate Dr. Eric Kandel, the meeting will cover how new technologies are providing fresh insights into the causes of rare diseases and ways forward for developing new treatments.

Featured topics include a new targeted therapy for cystic fibrosis, exon skipping for treating muscular dystrophy, gene therapy for SCID and hemophilia, tailoring treatments with genomics, and embryonic stem cell therapy for treating retinal diseases. Joining Science Translational Medicine, AAAS and the DMM Global Foundation in launching Days of Molecular Medicine 2012 are the following co-organizers: the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Ludwig Maximilians University Munich, the Karolinska Institute, and Fondation Ipsen.

Days of Molecular Medicine 2012 is also made possible through the generous sponsorship of Boehringer Ingleheim, Inc.

"The Days of Molecular Medicine 2012 conference will discuss the many different causes of rare diseases," says Orla Smith, Managing Editor of Science Translational Medicine, "and the diverse roster of speakers will provide fresh insights into how we can develop effective new treatments."

"From cystic fibrosis to hemophilia, there are a number of diseases that, while classified as "rare", afflict a significant number of people worldwide," says Ken Chien, DMM Global Foundation Director. "With enough attention from the research community, and the application of cutting-edge technology, we can start to bring much needed relief to patients and their families. That's what DMM 2012 is all about."

"Rare diseases often come with unspeakable suffering where children are mainly affected. It is a matter of great importance to me to support every effort to share knowledge and develop new ideas, which will hopefully turn into added value for the patients, " says  Dr. Josef Penninger of the IMBA.  "Therefore, it is a special honor for me to host this year's Days of Molecular Medicine Meeting here in Vienna on this very topic."

For further information and to register for the meeting visit dmm.aaas.org.

About AAAS/Science Translational Medicine
The American Association for the Advancement of Science (AAAS), the world's largest general scientific society, is the publisher of the journal Science (www.sciencemag.org) and the sister journals Science Translational Medicine (www.sciencetranslationalmedicine.org) and Science Signaling (www.sciencesignaling.org). The goal of Science Translational Medicine, launched in October 2009, is to promote human health by providing a forum for communicating the latest biomedical research findings from all established and emerging disciplines relevant to medicine. Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. Science Translational Medicine seeks to publish articles that identify and fill the scientific knowledge gaps at the junction of basic research and medical application in order to accelerate the translation of this knowledge into new ways to prevent, diagnose and treat human disease.

About DMM Global Foundation
The DMM Global Foundation is dedicated to promoting the career pathways for physician scientists.  Over the past decade, the members of the Foundation have worked to initiate and establish DMM as one of the leading scientific forums to champion the importance of translational science and medicine via partnerships with leading international institutions, foundations, and scientific publishing groups. The Foundation is proud to be a co organizer and sponsor of DMM 2012.    

About IMBA
The Institute of Molecular Biotechnology (IMBA) is a basic research institute of the Austrian Academy of Sciences. Here, an international team of scientists conducts primary research to study molecular mechanisms of biological processes and to address questions in modern life sciences and biomedicine. The aim is to understand the elementary mechanisms of health and disease. To reach this goal a wide array of model organisms as well as advanced technologies in cell biology, structural biology, biochemistry, genomics and genetics are used.

Media Contact: Natasha Pinol, AAAS, 202-326-6440, npinol@aaas.org

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE AAAS
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
4. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
5. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical ... heart failure, today announced that it intends to offer shares ... an underwritten public offering.  The offering is subject to market ... to whether or when the offering may be completed, or ...   --> --> Roth ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
(Date:2/9/2016)... This TforG report includes the Surgical Procedures Database with ... in South Korea . To add ... written and numerical analysis on the current trends, size, ... latest reforms of the local Healthcare system are clearly ... The report helps businesses gain a unique insight into ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... them of the lives they’ve led and the people they’ve touched. , That’s ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling ... handle, you are not alone. According to the Center for Disease Control and Prevention ... type 2 diabetes and certain types of cancer, some of the leading causes of ...
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):